A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)
Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The investigators will be looking at MAO-A density before and after seven weeks of treatment
with an antidepressant and dietary supplement. MAO-A is an enzyme that breaks down brain
chemicals that regulate mood. MAO-A density is elevated in patients with major depressive
episodes (MDE) secondary to major depressive disorder (MDD). Many remain treatment resistant
with common antidepressant treatments and we think it may be due to poor targeting of brain
pathologies. We want to test if adding a dietary supplement may normalize MAO-A.